Page last updated: 2024-11-07

aphidicolin glycinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

aphidicolin glycinate: DNA polymerase II inhibitor; RN given refers to(HCL(3R-(3alpha,4alpha,4aalpha,6abeta,8beta,9beta,11abeta,11bbeta)-isomer); RN for parent cpd without isomeric designation not avail 5/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21883635
MeSH IDM0186527

Synonyms (1)

Synonym
aphidicolin glycinate

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" We investigated the pharmacokinetics of aphidicolin in mice and examined its activity either alone or in combination with DDP in the DDP-sensitive M5076 (M5) murine reticular cell sarcoma as well as in a DDP-resistant subline (M5/DDP)."( Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Cavalli, F; D'Incalci, M; Damia, G; Davoli, E; Sessa, C; Tagliabue, G; Zucchetti, M, 1992
)
0.28
" Thus, we evaluated AG in combination with cisplatin in an in vivo model of cisplatin refractory human ovarian cancer."( Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
Cysyk, R; Hamilton, TC; Harrison, SD; Moyer, JD; O'Dwyer, PJ; Plowman, J; Suffness, M, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]